Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Praxis Precision Medicines (Nasdaq: PRAX) announced on Dec 1, 2025 that its Compensation Committee granted restricted stock unit awards covering 3,594 shares to six new non-executive employees under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards were issued as inducements material to the employees joining Praxis and will vest in four equal annual installments, subject to continued employment on each vesting date. The 2024 Inducement Plan is limited to equity awards for individuals not previously employed by Praxis or returning after a bona fide break in service.

News Market Reaction – PRAX

+2.05%

19 alerts

+2.05% News Effect

+55.8% Peak in 30 hr 27 min

+$100M Valuation Impact

$4.99B Market Cap

0.9x Rel. Volume

On the day this news was published, PRAX gained 2.05%, reflecting a moderate positive market reaction. Argus tracked a peak move of +55.8% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $100M to the company's valuation, bringing the market cap to $4.99B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement RSUs granted: 3,594 shares New employees: 6 employees Vesting schedule: 4 annual installments

3 metrics

Inducement RSUs granted 3,594 shares Awards to six new non-executive employees on Dec 1, 2025

New employees 6 employees Recipients of inducement restricted stock units

Vesting schedule 4 annual installments RSUs vest over four equal annual installments

Market Reality Check

Price: $290.10 Vol: Volume 513,975 is 0.46x t...

low vol

$290.10 Last Close

Volume Volume 513,975 is 0.46x the 20-day average of 1,122,459, indicating subdued trading. low

Technical Shares at 267.28, trading well above the 200-day MA 72.26, reflecting a strong pre-news uptrend.

Peers on Argus

Peer moves were mixed, with AVXL, SANA and ZBIO up between 1.63% and 2.7%, while...

Peer moves were mixed, with AVXL, SANA and ZBIO up between 1.63% and 2.7%, while EYPT and NKTR declined 4.28% and 10.83%, suggesting stock-specific rather than broad sector drivers for PRAX.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	FDA pathway update	Positive	-4.7%	FDA alignment on simplified, accelerated registrational pathway for elsunersen.
Dec 08	Clinical data update	Positive	+9.3%	AES presentations showing strong seizure reduction data for relutrigine and vormatrigine.
Dec 04	Topline trial results	Positive	+3.0%	Positive registrational EMBOLD topline with early stop for efficacy in DEEs.
Dec 04	Pre-NDA FDA meeting	Positive	+3.0%	Pre-NDA meeting for ulixacaltamide with alignment on NDA content and timing.
Dec 03	Inducement equity grants	Neutral	+3.9%	Inducement RSU awards of 3,594 shares to new employees under 2024 plan.

Pattern Detected

Recent fundamentally positive FDA and clinical updates usually saw positive price reactions, with one notable divergence when FDA pathway news coincided with a selloff.

Recent Company History

Over the past week, Praxis reported multiple regulatory and clinical milestones alongside capital markets activity. Positive topline EMBOLD data, AES clinical updates, and a pre-NDA meeting for ulixacaltamide all saw share gains of around 3–9%. In contrast, FDA alignment on a simplified registrational pathway for elsunersen on Dec 9, 2025 was followed by a -4.74% move, highlighting at least one divergence. The current inducement grant on Dec 1, 2025 is a routine HR-related equity event, much smaller than the October underwritten offering detailed in recent filings.

Market Pulse Summary

This announcement details routine equity-based inducement awards of 3,594 shares to six new employee...

Analysis

This announcement details routine equity-based inducement awards of 3,594 shares to six new employees under the 2024 Inducement Plan, vesting over four years in line with Nasdaq Listing Rule 5635(c)(4). In context, Praxis has recently issued much larger equity offerings and reported significant clinical and regulatory milestones across ulixacaltamide, relutrigine, vormatrigine and elsunersen. Investors may monitor how incremental equity issuance, insider trading activity, and future trial or FDA updates interact with the already elevated share price relative to the 200-day MA 72.26.

Key Terms

restricted stock unit awards, nasdaq listing rule 5635(c)(4), central nervous system (cns), restricted stock units

4 terms

restricted stock unit awards financial

"granted restricted stock unit awards covering an aggregate of 3,594 shares"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

central nervous system (cns) medical

"therapies for central nervous system (CNS) disorders characterized by neuronal"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

restricted stock units financial

"The restricted stock units will vest in four equal annual installments"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. Not financial advice.

BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on December 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,594 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.

Contacts:
Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What did Praxis (PRAX) announce on December 1, 2025 regarding equity grants?

Praxis granted restricted stock unit awards covering 3,594 shares to six new non-executive employees under the 2024 Inducement Plan.

Why were the restricted stock units issued under Nasdaq Listing Rule 5635(c)(4) for PRAX?

The awards were issued as inducements material to new hires, permitted by Nasdaq Listing Rule 5635(c)(4) for employees not previously employed or returning after a bona fide break.

How do the Praxis PRAX restricted stock units vest?

The restricted stock units will vest in four equal annual installments, contingent on each employee’s continued employment on each vesting date.

How many employees received inducement grants in the Praxis PRAX announcement?

Six new non-executive employees received restricted stock unit awards totaling 3,594 shares.

Does the Praxis PRAX announcement include executive stock grants or only non-executive hires?

The announcement specifies awards to six new non-executive employees, not to current executives.

What is the purpose of Praxis’s 2024 Inducement Plan mentioned in the PRAX filing?

The 2024 Inducement Plan is used exclusively to grant equity awards as inducements to individuals who were not previously employees or who returned after a bona fide non-employment period.